The global medical device market continues to expand, with aging trends and technological innovation providing long-term growth momentum for industry leaders. Companies such as Abbott Laboratories (ABT), GE Healthcare Technologies (GEHC), and Intuitive Surgical (ISRG) possess competitive advantages in their respective niche segments, and their solid fundamentals and sustained innovation capabilities make them worthy of attention. However, when positioning in this sector, investors still need to carefully assess potential risk factors such as the competitive landscape, regulatory environment, and product safety, and make rational investment decisions.
As a major medical device enterprise, Abbott Laboratories’ product line encompasses continuous glucose monitoring systems, defibrillators, heart failure monitoring systems, mechanical heart valves, pacemakers, and spinal cord stimulators. The company also operates multi-billion-dollar business segments involving established pharmaceuticals, diagnostic systems, and nutritional products.
During the COVID-19 pandemic, the company’s rapid diagnostic testing products significantly boosted its performance. Although overall revenue has declined as testing demand waned, its core business remains robust. Of particular note, the FreeStyle Libre, as the world’s best-selling continuous glucose monitoring system, has become a key growth engine for the company. For investors seeking stable returns, the company has raised its dividend for 54 consecutive years and is one of the S&P 500 Dividend Aristocrats.
The company was spun off from General Electric in 2023, but it has maintained a leading position in the medical device market for decades. The enterprise operates four major business segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Among these, the medical imaging business is the largest revenue source, contributing over 40% of total revenue in 2025.
Like many medical device stocks, GE Healthcare stands to benefit from the global trend of population aging. As age increases, the demand for medical services among the elderly continues to rise, which will directly drive demand for the company’s products. The company has a strong track record of innovation, with annual R&D investment exceeding $1 billion, laying a solid foundation for seizing market opportunities.
The company is a pioneer in minimally invasive robotic surgical systems. Its flagship product, the da Vinci Surgical System, was introduced in 1999 and was initially approved for general laparoscopic surgeries. It has since been widely adopted for a variety of surgical procedures. To date, more than 20.4 million surgeries worldwide have been performed using the da Vinci system, with approximately 3.2 million procedures completed in 2025 alone. More than 12,000 da Vinci systems have been installed in hospitals globally.
Except for a brief slowdown during the COVID-19 pandemic, the company’s surgical volume has maintained steady growth in recent years, driving an increase in recurring revenue from replacement instrument sales. In 2025, recurring revenue accounted for 84% of the company’s total revenue. The aging population trend will drive increased demand for surgeries, while the company’s continuous upgrades to its robotic surgical systems and expansion into more surgical indications further solidify its market position.
Investing in medical device stocks offers multiple advantages. First, this sector directly benefits from the aging demographic structure in developed countries; second, technological advancements are expected to create significant growth opportunities; moreover, medical device stocks typically demonstrate strong resilience during market volatility. However, investors should also be alert to related risks. Clinical trial failures and regulatory hurdles can cause substantial stock price declines; some medical device segments face intense competition; and product liability and safety issues can likewise negatively impact stock prices.
